|
|
Facebook sets up a mechanism for its users to declare their organ donor status. |
|
CNN: The Facebook tool works like this: Users go to their timelines, where under Life Event they will see a health and wellness section. Zuckerberg said: "You put in, 'I decided to be an organ donor' and your state or country you live in and you can add a story about how you decided to be an organ donor." A Facebook user will also see a Share Your Donor Status link when a friend's donor update hits their news feed.
|
|
|
Renal denervation devicemakers in the news: Covidien and Maya medical. |
|
Med City News: A Covidien spokesman wouldn’t comment what he described as “market rumors and speculation” but conceded that the company is in “partnership with Maya on a new technology.” The spokesman, Bruce Farmer, went on to add that Covidien makes strategic investments from time to time and “is a recognized market leader in RF ablation technology, with numerous products in both its Vascular and Surgical portfolios…”
|
|
Nephros gets 510k approval from FDA for it's add-on hemodiafiltration module. |
|
Sacramento Bee: Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications and advanced water purification solutions, today announced the Company has received 510(k) clearance from the Food and Drug Administration ("FDA") to market its Hemodiafiltration ("HDF") system for the treatment of chronic renal failure when used with UF controlled dialysis machines capable of producing ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.
|
|
Avastin and Lucentis similarly effective in treating wet age-related macular degeneration. |
|
EurekAlert: "Both drugs were highly effective regardless of the approach to dosing," said Daniel F. Martin M.D., study chair for CATT and Chairman of the Cole Eye Institute at the Cleveland Clinic. "There was slightly less vision gain with as-needed treatment. However, patients seeking the small extra advantage of monthly treatment need to be mindful of the additional burden, risks, and costs of monthly injections. Since as-needed dosing required 10 fewer eye injections over the course of two years and yielded similar visual results, many patients may choose this option."
|
|
Synthetic stool a potential treatment for chronic C. dificile infection. |
|
EurekAlert: Dr. Petrof and Dr. Allen Vercoe, an anaerobic microbiologist specializing in intestinal bacteria, are working closely to develop such a therapy. The goal behind their synthetic stool project is to offer a single-dose remedy, putting an end to revolving-door hospital visits for patients with recurring symptoms. Currently, they are continuing their research before using it as a new therapy.
|
|
|
|
|
<< Start < Prev 411 412 413 414 415 416 417 418 419 420 Next > End >>
|
|
Page 414 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
